CN Patent

CN102985417A — 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物

Assigned to Because of C1-esteraseremmer-N parent corporation · Expires 2013-03-20 · 13y expired

What this patent protects

本发明提供了哌啶-4-基氮杂环丁烷衍生物、以及其组合物和使用方法，它们调节Janus激酶1(JAK1)的活性并且可用于治疗与JAK1的活性相关的疾病，包括例如炎症性病症、自身免疫性病症、癌症和其它疾病。

USPTO Abstract

本发明提供了哌啶-4-基氮杂环丁烷衍生物、以及其组合物和使用方法，它们调节Janus激酶1(JAK1)的活性并且可用于治疗与JAK1的活性相关的疾病，包括例如炎症性病症、自身免疫性病症、癌症和其它疾病。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN102985417A
Jurisdiction: CN
Classification: —
Expires: 2013-03-20
Drug substance claim: No
Drug product claim: No
Assignee: Because of C1-esteraseremmer-N parent corporation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.